The Conversation (0)
Ares Life Sciences, an investment group focused on health care, announced its 100% acquisition of the share capital of Antigen Laboratories Inc’s wholly owned Planet Biopharmaceuticals Inc.
Ares Life Sciences, an investment group focused on health care, announced its 100% acquisition of the share capital of Antigen Laboratories Inc’s wholly owned Planet Biopharmaceuticals Inc.
As quoted in the press release:
Ares recently signed an agreement to acquire Greer Laboratories, Inc. a leader in U.S. allergy immunotherapy (AIT) market. The acquisition of Antigen Laboratories is a continuation of Ares’ strategic focus on the U.S. AIT market. It is also the majority shareholder of the French based Stallergenes S.A., a pioneer and leader in immunotherapy treatments by sublingual administration. Ares believes there is significant growth potential in the AIT business globally, particularly in the US which currently only represents 10% of the European market and is expected to grow significantly over the next few years.
Click here to read the full Ares Life Sciences press release.
